





OUR PERFORMANCE

Synlait was established in 2000. As a company we are proud of what we have achieved over the last 20 years.

Synlait had a strong financial result in FY20. These graphs show details of our results for the five financial periods from FY16 to FY20 featuring two key indicators, firstly our earnings before interest, tax, depreciation and amortisation (EBITDA) and secondly our revenue. We are well positioned to grow earnings off our current asset base.



STRONG FINANCIAL RESULT DELIVERED IN FY20

- Synlait remains a solid and highly profitable business despite COVID-19.
- EBITDA grew strongly demonstrating the strength of our infant and lactoferrin businesses.
- NPAT reduced reflecting investments in new facilities and acquisitions over the past two years to create new opportunities for growth.
- We continue to balance people and planet with profit.

KEY FINANCIAL HIGHLIGHTS



▲ 27%
\$1.3B

REVENUE



▲ 9%
\$203.7M

GROSS PROFIT



▲ 13%
\$171.4M

EBITDA



▲ 15%
49,180MT

CONSUMER-PACKAGED INFANT
FORMULA SALES



▼ 9%
\$75.2M

NPAT



▲ 46%
30MT

LACTOFERRIN SALES